drugset
drugset / Trial / NCT05152901

Study of Inhaled Epinephrine and Intramuscular Epinephrine Administered to Healthy Adults

NCT05152901 ↗

Phase 1 Completed 23 enrolled De Motu Cordis Novotech (Australia) Pty Limited · collab
Non-randomizedSequentialOpen-labelTreatment

Summary

This is a study to determine the relative bioavailability of inhaled epinephrine compared with 0.3mg epinephrine administered IM in healthy male and female participants.

Timeline

Start
2022-01-06
Primary completion
2022-06-06
Completion
2022-06-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Epinephrine Other / unclassified 0.3 mg Intramuscular
Comparator Epinephrine Other / unclassified 1.3 mg Intramuscular
Comparator Epinephrine Other / unclassified 4 mg Intramuscular

Indications

anaphylaxis